SBHM.Y Stock Overview
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.20 |
| 52 Week High | HK$11.18 |
| 52 Week Low | HK$6.69 |
| Beta | 0.52 |
| 1 Month Change | -12.20% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -66.63% |
| 5 Year Change | -44.27% |
| Change since IPO | -15.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBHM.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -3.2% |
| 1Y | n/a | 9.7% | 19.3% |
Return vs Industry: Insufficient data to determine how SBHM.Y performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SBHM.Y performed against the US Market.
Price Volatility
| SBHM.Y volatility | |
|---|---|
| SBHM.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBHM.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SBHM.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection.
Sino Biopharmaceutical Limited Fundamentals Summary
| SBHM.Y fundamental statistics | |
|---|---|
| Market cap | US$5.48b |
| Earnings (TTM) | US$255.13m |
| Revenue (TTM) | US$3.62b |
21.5x
P/E Ratio1.5x
P/S RatioIs SBHM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBHM.Y income statement (TTM) | |
|---|---|
| Revenue | CN¥26.20b |
| Cost of Revenue | CN¥4.99b |
| Gross Profit | CN¥21.21b |
| Other Expenses | CN¥19.36b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 80.95% |
| Net Profit Margin | 7.05% |
| Debt/Equity Ratio | 32.0% |
How did SBHM.Y perform over the long term?
See historical performance and comparison